FDA Approves First PARP Inhibitor for Early BRCA+ Breast Cancer

Overall survival results showing a 32% reduction in mortality with olaparib vs placebo will be presented at an upcoming EMSO virtual plenary session.
FDA Approvals
Overall survival results showing a 32% reduction in mortality with olaparib vs placebo will be presented at an upcoming EMSO virtual plenary session.
FDA Approvals